Marcus Schlemmer

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi The role of hyperthermia in combined treatment in the management of soft tissue sarcoma
    Rolf D Issels
    University Hospital Medical Center Grosshadern Medical Clinic III, GSF National Research Center for the Environment and Health, 81377 Munich, Germany
    Curr Oncol Rep 8:305-9. 2006
  2. ncbi Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors
    Marcus Schlemmer
    Department of Internal Medicine III Hematology Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany
    J Gastrointest Cancer 43:385-7. 2012
  3. ncbi Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response
    Dominik Ruttinger
    Department of Surgery, Grosshadern Medical Center, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    J Transl Med 5:43. 2007
  4. ncbi Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial
    Marcus Schlemmer
    Depart Medical Oncology Klinikum Grosshadern, Munich, Germany
    Eur J Med Res 16:206-12. 2011
  5. ncbi Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group
    M Schlemmer
    Medical Clinic and Polyclinc III, Clinic Grosshadern Munich, Ludwig Maximilian University Munich, Muenchen, Germany
    Eur J Cancer 44:2433-6. 2008
  6. ncbi Desmoid tumors and deep fibromatoses
    Marcus Schlemmer
    Medical Clinic and Polyclinic III, Clinic Grosshadern Munich, Ludwig Maximilian University Munich, Marchioninistrasse 15, Muenchen D 81377, Germany
    Hematol Oncol Clin North Am 19:565-71, vii-viii. 2005
  7. ncbi Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas
    Marcus Schlemmer
    Department of Internal Medicine III, Klinikum Grosshadern Medical Center, Munich, Germany
    Oncology 71:32-9. 2006
  8. ncbi [Principles, technology and indication of hyperthermia and part body hyperthermia]
    M Schlemmer
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern der Universität München
    Radiologe 44:301-9. 2004
  9. ncbi Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS)
    M Schlemmer
    Department of Internal Medicine III, Klinikum Grosshadern Medical Centre, Ludwig Maximilians University Munich, Germany
    Int J Hyperthermia 26:127-35. 2010
  10. ncbi Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy
    Marcus Schlemmer
    Department of Internal Medicine III, University Hospitals Großhadern, Ludwig Maximilians University Munich, Marchioninistr 15, 81377 Munich, Germany
    Eur J Radiol 77:312-8. 2011

Detail Information

Publications22

  1. ncbi The role of hyperthermia in combined treatment in the management of soft tissue sarcoma
    Rolf D Issels
    University Hospital Medical Center Grosshadern Medical Clinic III, GSF National Research Center for the Environment and Health, 81377 Munich, Germany
    Curr Oncol Rep 8:305-9. 2006
    ..This short overview summarizes the results of the combination with regional hyperthermia as a new treatment strategy to open a new therapeutic window...
  2. ncbi Response to nilotinib as a first-line treatment for metastatic gastrointestinal stromal tumors
    Marcus Schlemmer
    Department of Internal Medicine III Hematology Oncology, University Hospital Munich Campus Grosshadern, Munich, Germany
    J Gastrointest Cancer 43:385-7. 2012
    ....
  3. ncbi Adjuvant therapeutic vaccination in patients with non-small cell lung cancer made lymphopenic and reconstituted with autologous PBMC: first clinical experience and evidence of an immune response
    Dominik Ruttinger
    Department of Surgery, Grosshadern Medical Center, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    J Transl Med 5:43. 2007
    ..This paper reports on the first clinical experience and evidence of an immune response in patients suffering from NSCLC...
  4. ncbi Activity and side effects of imatinib in patients with gastrointestinal stromal tumors: data from a German multicenter trial
    Marcus Schlemmer
    Depart Medical Oncology Klinikum Grosshadern, Munich, Germany
    Eur J Med Res 16:206-12. 2011
    ..The safety profile of imatinib based on adverse event assessment is favorable. Imatinib is generally well tolerated in patients with gastrointestinal stromal tumors...
  5. ncbi Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group
    M Schlemmer
    Medical Clinic and Polyclinc III, Clinic Grosshadern Munich, Ludwig Maximilian University Munich, Muenchen, Germany
    Eur J Cancer 44:2433-6. 2008
    ..The objective of this retrospective study was to assess the anti-tumour activity of this compound in a multicentre setting...
  6. ncbi Desmoid tumors and deep fibromatoses
    Marcus Schlemmer
    Medical Clinic and Polyclinic III, Clinic Grosshadern Munich, Ludwig Maximilian University Munich, Marchioninistrasse 15, Muenchen D 81377, Germany
    Hematol Oncol Clin North Am 19:565-71, vii-viii. 2005
    ..Treatment primarily is surgical, although radiation or systemic therapy can be beneficial to the patient when surgery is not feasible. This article highlights the biology and clinical features of desmoid tumors...
  7. ncbi Efficacy of consolidation high-dose chemotherapy with ifosfamide, carboplatin and etoposide (HD-ICE) followed by autologous peripheral blood stem cell rescue in chemosensitive patients with metastatic soft tissue sarcomas
    Marcus Schlemmer
    Department of Internal Medicine III, Klinikum Grosshadern Medical Center, Munich, Germany
    Oncology 71:32-9. 2006
    ..We report phase II data of high-dose chemotherapy and peripheral blood stem cell (PBSC) rescue in patients with MSTS responding to AI-G chemotherapy...
  8. ncbi [Principles, technology and indication of hyperthermia and part body hyperthermia]
    M Schlemmer
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern der Universität München
    Radiologe 44:301-9. 2004
    ..The results shows, that response to treatment can be improved by hyperthermia...
  9. ncbi Thermochemotherapy in patients with extremity high-risk soft tissue sarcomas (HR-STS)
    M Schlemmer
    Department of Internal Medicine III, Klinikum Grosshadern Medical Centre, Ludwig Maximilians University Munich, Germany
    Int J Hyperthermia 26:127-35. 2010
    ....
  10. ncbi Perfusion patterns of metastatic gastrointestinal stromal tumor lesions under specific molecular therapy
    Marcus Schlemmer
    Department of Internal Medicine III, University Hospitals Großhadern, Ludwig Maximilians University Munich, Marchioninistr 15, 81377 Munich, Germany
    Eur J Radiol 77:312-8. 2011
    ..The aim of this pilot study was the evaluation of CT perfusion patterns in metastatic GIST lesions under specific molecular therapy with sunitinib or imatinib both in responders and non-responders...
  11. ncbi Ifosfamide with regional hyperthermia in soft-tissue sarcomas
    M Schlemmer
    Department of Internal Medicine III, Klinikum Grosshadern Medical Center, Ludwig Maximilians University Munich, Munich, Germany
    Oncology 65:76-9. 2003
    ..The combination with regional hyperthermia as a new treatment strategy seems to open a new therapeutic window...
  12. ncbi Ifosfamide, carboplatin and etoposide (ICE) as second-line regimen alone and in combination with regional hyperthermia is active in chemo-pre-treated advanced soft tissue sarcoma of adults
    M Fiegl
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig-Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Int J Hyperthermia 20:661-70. 2004
    ..Median overall survival for all patients was 14.6 months. CONCLUSION: These results suggest that ICE alone or combined with RHT shows activity as second-line therapy in doxorubicin-ifosfamide-refractory STS...
  13. ncbi Immunotherapy of lung cancer: an update
    Dominik Ruttinger
    Chirurgische Klinik und Poliklinik, Abteilung für Transfusionsmedizin und Hämostaseologie, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Munchen, Germany
    Onkologie 29:33-8. 2006
    ..Although there seems to be a promising future for immunotherapy in lung cancer, presently there is not standard immunotherapy available for clinical routine...
  14. ncbi The cause of subchondral bone cysts in osteoarthrosis: a finite element analysis
    Hans D Dürr
    Department of Orthopaedics and Orthopaedic Surgery, Ludwig Maximilians University Munich, Klinikum Grosshadern, Marchioninistr 15, DE 81366 Munich, Germany
    Acta Orthop Scand 75:554-8. 2004
    ..The etiology of subchondral bone cysts in arthrotic joints is unclear...
  15. ncbi [Gastrointestinal stromal tumors]
    M Schlemmer
    Medizinische Klinik und Poliklinik III, , Munich
    Dtsch Med Wochenschr 128:2015-9. 2003
  16. ncbi Current trials and new aspects in soft tissue sarcoma of adults
    R D Issels
    Department of Internal Medicine III, Klinikum Grosshadern Medical Center, Ludwig Maximilians University, Munich, Germany
    Cancer Chemother Pharmacol 49:S4-8. 2002
    ..Therefore, systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS...
  17. ncbi Paramagnetic thermosensitive liposomes for MR-thermometry
    L H Lindner
    Department of Medicine III, University Hospital Grosshadern, CCG Hyperthermia, GSF National Research Center for Environment and Health, Ludwig Maximilians University, Munich, Germany
    Int J Hyperthermia 21:575-88. 2005
    ..Nevertheless, before entering clinical trials they have to be studied in more detail with regard to dose, pharmacokinetics and toxicity...
  18. ncbi Tissue levels of reduced folates in patients with colorectal carcinoma after infusion of folinic acid at various dose levels
    Marcus Schlemmer
    Department of Internal Medicine III, Ludwig Maximilians University Grobetahadern, Marchioninistr 15, Munich, Germany
    Clin Cancer Res 14:7930-4. 2008
    ..However, the optimal dose of FA is still debated. We investigated reduced folate pools in various tissues from patients with CRC without and after prior administration of FA...
  19. ncbi Gene expression profiling in sarcomas
    Katharina Tschoep
    Medizinische Klinik und Poliklinik III, Ludwig Maximilians University, Medical Center Grosshadern, Munich, Germany
    Crit Rev Oncol Hematol 63:111-24. 2007
    ....
  20. ncbi [Gene expression analysis using DNA microarrays in soft tissue and bone tumors]
    K Tschoep
    Medizinische Klinik und Poliklinik III, , Klinikum Grosshadern, Munich
    Dtsch Med Wochenschr 128:2030-6. 2003
  21. ncbi Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg
    John R Zalcberg
    Department of Medical Oncology, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Locked Bag 1, A Beckett Street, Melbourne, VIC 8006, Australia
    Eur J Cancer 41:1751-7. 2005
    ..1% of patients were still alive and progression free one year after cross-over. We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy...
  22. ncbi Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up
    P G Casali
    Department of Cancer Medicine, Istituto Nazionale dei Tumori, Milan, Italy
    Ann Oncol 19:ii89-93. 2008